Safety of COVID-19 Vaccines: Spotlight on Neurological Complications

Overview

Journal Life (Basel)

Specialty Biology

Date 2022 Sep 23

PMID 36143376

Authors

Giacomo Tondo

Eleonora Virgilio

Andrea Naldi

Angelo Bianchi

Cristoforo Comi

Affiliations

Soon will be listed here.

Abstract

The COVID-19 pandemic has led to unprecedented demand on the global healthcare system. Remarkably, at the end of 2021, COVID-19 vaccines received approvals for human use in several countries worldwide. Since then, a solid base for response in the fight against the virus has been placed. COVID-19 vaccines have been shown to be safe and effective drugs. Nevertheless, all kinds of vaccines may be associated with the possible appearance of neurological complications, and COVID-19 vaccines are not free from neurological side effects. Neurological complications of COVID-19 vaccination are usually mild, short-duration, and self-limiting. However, severe and unexpected post-vaccination complications are rare but possible events. They include the Guillain-Barré syndrome, facial palsy, other neuropathies, encephalitis, meningitis, myelitis, autoimmune disorders, and cerebrovascular events. The fear of severe or fatal neurological complications fed the "vaccine hesitancy" phenomenon, posing a vital communication challenge between the scientific community and public opinion. This review aims to collect and discuss the frequency, management, and outcome of reported neurological complications of COVID-19 vaccines after eighteen months of the World Health Organization's approval of COVID-19 vaccination, providing an overview of safety and concerns related to the most potent weapon against the SARS-CoV-2.

Citing Articles

Exploring the adverse events of Oxford-AstraZeneca, Pfizer-BioNTech, Moderna, and Johnson and Johnson COVID-19 vaccination on Guillain-Barré Syndrome.

Meo S, Shaikh N, Abukhalaf F, Meo A Sci Rep. 2024; 14(1):18767.

PMID: 39138276 PMC: 11322667. DOI: 10.1038/s41598-024-66999-7.

The Neurological Implications of COVID-19: A Comprehensive Narrative Review.

Cheyne I, Gopinath V, Muppa N, Armas A, Gil Agurto M, Akula S Cureus. 2024; 16(5):e60376.

PMID: 38887342 PMC: 11181960. DOI: 10.7759/cureus.60376.

Serum SARM1 Levels and Diabetic Peripheral Neuropathy in Type 2 Diabetes: Correlation with Clinical Neuropathy Scales and Nerve Conduction Studies and Impact of COVID-19 vaccination.

Alrawaili M, Abuzinadah A, AlShareef A, Hindi E, Bamaga A, Alshora W Vaccines (Basel). 2024; 12(2).

PMID: 38400192 PMC: 10892204. DOI: 10.3390/vaccines12020209.

Relative effectiveness of bivalent COVID-19 vaccine: a systematic review and meta-analysis.

Cheng M, Li R, Weng Z, Song G Front Med (Lausanne). 2024; 10:1322396.

PMID: 38384317 PMC: 10879625. DOI: 10.3389/fmed.2023.1322396.

NEURO-COVAX: An Italian Population-Based Study of Neurological Complications after COVID-19 Vaccinations.

Salsone M, Signorelli C, Oldani A, Alberti V, Castronovo V, Mazzitelli S Vaccines (Basel). 2023; 11(10).

PMID: 37897023 PMC: 10610846. DOI: 10.3390/vaccines11101621.

References

Oliver S, Wallace M, See I, Mbaeyi S, Godfrey M, Hadler S . Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices - United States, December 2021. MMWR Morb Mortal Wkly Rep. 2022; 71(3):90-95. PMC: 8774160. DOI: 10.15585/mmwr.mm7103a4. View

van de Munckhof A, Krzywicka K, Aguiar de Sousa D, Sanchez van Kammen M, Heldner M, Jood K . Declining mortality of cerebral venous sinus thrombosis with thrombocytopenia after SARS-CoV-2 vaccination. Eur J Neurol. 2021; 29(1):339-344. PMC: 8652752. DOI: 10.1111/ene.15113. View

Noseda R, Ripellino P, Ghidossi S, Bertoli R, Ceschi A . Reporting of Acute Inflammatory Neuropathies with COVID-19 Vaccines: Subgroup Disproportionality Analyses in VigiBase. Vaccines (Basel). 2021; 9(9). PMC: 8473382. DOI: 10.3390/vaccines9091022. View

Ibrahim Ismail I, Salama S . A systematic review of cases of CNS demyelination following COVID-19 vaccination. J Neuroimmunol. 2021; 362:577765. PMC: 8577051. DOI: 10.1016/j.jneuroim.2021.577765. View

Min Y, Kim J, Hwang J, Shin J, Sung J, Hong Y . Parsonage-Turner syndrome following COVID-19 vaccination. J Neurol Neurosurg Psychiatry. 2022; . PMC: 9606495. DOI: 10.1136/jnnp-2021-328182. View

Nishiguchi Y, Matsuyama H, Maeda K, Shindo A, Tomimoto H . Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination. BMC Neurol. 2021; 21(1):452. PMC: 8598937. DOI: 10.1186/s12883-021-02489-x. View

Gao J, Tseng H, Lin C, Shiu J, Lee M, Liu C . Acute Transverse Myelitis Following COVID-19 Vaccination. Vaccines (Basel). 2021; 9(9). PMC: 8470728. DOI: 10.3390/vaccines9091008. View

Allen C, Ramsamy S, Tarr A, Tighe P, Irving W, Tanasescu R . Guillain-Barré Syndrome Variant Occurring after SARS-CoV-2 Vaccination. Ann Neurol. 2021; 90(2):315-318. DOI: 10.1002/ana.26144. View

Al-Quliti K, Qureshi A, Quadri M, Abdulhameed B, Alanazi A, Alhujeily R . Acute Demyelinating Encephalomyelitis Post-COVID-19 Vaccination: A Case Report and Literature Review. Diseases. 2022; 10(1). PMC: 8884009. DOI: 10.3390/diseases10010013. View

10.

Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P . Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis. 2021; 21(7):939-949. PMC: 8078878. DOI: 10.1016/S1473-3099(21)00224-3. View

11.

Ozonoff A, Nanishi E, Levy O . Bell's palsy and SARS-CoV-2 vaccines. Lancet Infect Dis. 2021; 21(4):450-452. PMC: 7906673. DOI: 10.1016/S1473-3099(21)00076-1. View

12.

Pegat A, Vogrig A, Khouri C, Masmoudi K, Vial T, Bernard E . Adenovirus COVID-19 Vaccines and Guillain-Barré Syndrome with Facial Paralysis. Ann Neurol. 2021; 91(1):162-163. PMC: 8652690. DOI: 10.1002/ana.26258. View

13.

de Gregorio C, Colarusso L, Calcaterra G, Bassareo P, Ieni A, Mazzeo A . Cerebral Venous Sinus Thrombosis following COVID-19 Vaccination: Analysis of 552 Worldwide Cases. Vaccines (Basel). 2022; 10(2). PMC: 8874972. DOI: 10.3390/vaccines10020232. View

14.

Taquet M, Geddes J, Husain M, Luciano S, Harrison P . 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021; 8(5):416-427. PMC: 8023694. DOI: 10.1016/S2215-0366(21)00084-5. View

15.

Klein N, Lewis N, Goddard K, Fireman B, Zerbo O, Hanson K . Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA. 2021; 326(14):1390-1399. PMC: 8511971. DOI: 10.1001/jama.2021.15072. View

16.

Ahmed I, Majeed A, Powell R . Heparin induced thrombocytopenia: diagnosis and management update. Postgrad Med J. 2007; 83(983):575-82. PMC: 2600013. DOI: 10.1136/pgmj.2007.059188. View

17.

McGonagle D, De Marco G, Bridgewood C . Mechanisms of Immunothrombosis in Vaccine-Induced Thrombotic Thrombocytopenia (VITT) Compared to Natural SARS-CoV-2 Infection. J Autoimmun. 2021; 121:102662. PMC: 8133385. DOI: 10.1016/j.jaut.2021.102662. View

18.

Ercoli T, Lutzoni L, Orofino G, Muroni A, Defazio G . Functional neurological disorder after COVID-19 vaccination. Neurol Sci. 2021; 42(10):3989-3990. PMC: 8319586. DOI: 10.1007/s10072-021-05504-8. View

19.

Kakovan M, Ghorbani Shirkouhi S, Zarei M, Andalib S . Stroke Associated with COVID-19 Vaccines. J Stroke Cerebrovasc Dis. 2022; 31(6):106440. PMC: 8894799. DOI: 10.1016/j.jstrokecerebrovasdis.2022.106440. View

20.

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View